Finally, CH present at diagnosis was not associated with known risk factors for myeloma progression, including beta-2 microglobulin, lactate dehydrogenase (LDH), International Staging System (ISS) score, and high-risk cytogenetic abnormalities (Table 1). The gene discussed is B2M; the disease is cyclic hematopoiesis.